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Debates about the indication and extent of LND are ongoing. 
Despite the benefits of staging accuracy and its possible therapeutic 
role in eliminating microscopic metastases, LND is also associated 
with several disadvantages, such as increased morbidity, longer 
operation time, and higher cost.9,10 Therefore, current guidelines do 
not recommend performing LND in all patients; however, extended 
LND  (eLND) should be performed in patients with a risk of LN 
metastases.11–13 Until date, several studies have reported the experiences 
and outcomes of eLND using robotic systems.14–16 With the growing 
use of RARP even in patients with high-risk of prostate cancer, it is 
valuable to share robotic eLND experiences as the role of LND should 
not be ignored in RARP. The objective of the current study is to present 
our robotic eLND experiences in prostate cancer surgery.
MATERIALS AND METHODS
From May 2008 to December 2011, a total of 234  patients with 
intermediate or high-risk prostate cancer underwent RARP with eLND. 
A single surgeon performed all procedures and the patient database 
was collected prospectively after obtaining Institutional Review Board 
Approval (1-2012-0024). Of the 234  patients, 47 with neoadjuvant 
hormonal treatment and 40 with incomplete LN information 
(including location or number) were excluded from the analysis. Thus, 
147 patients were finally included in this study. Risk stratification was 
INTRODUCTION
Radical prostatectomy is a mainstay treatment for men with localized 
prostate cancer. Following the first descriptions of the robot-assisted 
laparoscopic technique,1 the use of surgical robots for treating prostate 
cancer has diffused rapidly over the past decade. Although there has 
been no large randomized clinical trial comparing robotic and open 
radical prostatectomy, robot-assisted radical prostatectomy (RARP) 
seems to offer oncologic outcomes comparable to those of open surgery 
even in patients with high-risk prostate cancer.2 Case volume, rather 
than surgical modality, is often considered a primary contributor to 
surgical outcome.3 However, there has recently been a statistically 
significant decline in the use of lymph node dissection  (LND). 
Furthermore, LND is 5 times less likely in minimally invasive surgery 
than in open surgery even after controlling for tumor characteristics.4 
This trend is particularly worrisome because surgical modality should 
not be a factor in deciding whether or not to perform LND.
Although the advent of prostate specific antigen (PSA) has resulted 
in stage migration with decreased incidence of LN metastases, the 
presence of LN metastases remain an adverse prognostic factor. 
Unfortunately, recent sophisticated imaging procedures have limited 
ability for nodal staging.5,6 In addition, most well-known nomograms 
might be imprecise as a result of differing extents of LND.7,8 Currently, 
LND is the gold standard for determining nodal staging.9
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In this study, we reported our experience performing robotic extended lymph node dissection (eLND) in patients with prostate 
cancer. A total of 147 patients with intermediate and high-risk prostate cancer who underwent robotic eLND from May 2008 
to December 2011 were included in this analysis. The dissection template extended to the ureter crossing the iliac vessels. We 
assessed lymph node yield, lymph node positivity, and perioperative outcomes. Lymph node positivity was also evaluated according 
to the number of lymph nodes (LNs) removed (<22 vs ≥22). The median number of LNs removed was 22 (11–51), and 97 positive 
LNs were found in 24 patients (16.3%). While the obturator fossa was the most common site for LN metastases (42.3%, 41/97), 
the internal iliac area was the most common area for a single positive LN packet (20.8%, 5/24). Eight patients (33.3%, 8/24) 
had positive LNs at the common iliac area. The incidence of positive LNs did not differ according to the number of LNs removed. 
Complications associated with eLND occurred in 21 patients (14.3%) and symptomatic lymphocele was found in five patients (3.4%). 
In conclusion, robotic eLND can be performed with minimal morbidity. Furthermore, LN yield and the node positive rate achieved 
using this robotic technique are comparable to those of open series. In addition, the extent of dissection is more important than 
the absolute number of LNs removed in eLND, and the robotic technique is not a prohibitive factor for performing eLND.
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based on D’Amico risk criteria.17 All patients underwent preoperative 
staging with computed tomography or magnetic resonance imaging 
and bone scan, which confirmed the absence of metastatic disease.
All procedures, including eLND, were conducted through a 
transperitoneal approach using the daVinci Surgical System (Intuitive 
Surgical, Sunnyvale, CA, USA). The port configuration is described 
in detail in our previous report.18 The eLND template consisted of the 
external iliac, obturator, internal iliac, and common iliac up to the 
ureteric crossing. In addition, the lymphofatty tissue of the periprostatic 
area was sent separately to pathology. All eLNDs were performed prior 
to radical prostatectomy. The peritoneal incisions commenced from 
the lateral to medial umbilical ligament. After the bladder was lowered, 
fatty tissues covering the vesicoprostatic junction and periprostatic area 
were removed. The peritoneal incision proceeded proximally up to the 
ureteric crossing over the iliac vessel, and the lymphatic tissue covering 
the common iliac artery was removed. Dissection of the external iliac 
packet was limited by the lateral border of the external iliac artery and 
inferiorly by the node of Cloquet. After dissecting the tissues around 
the common iliac artery and its bifurcation area, the internal iliac artery 
was identified and nodal tissues around the internal iliac were removed. 
Lymphatic tissues within the obturator fossa were also removed, sparing 
the obturator nerve. The LNs were retrieved by laparoscopic forceps 
through a 12 mm assistant trocar site. LN specimens from each packet 
were sent separately for pathological analysis.
Next, LN specimens were fixed in 10% neural buffered formalin 
and embedded in a paraffin block. Slides were then stained with 
hematoxylin and eosin and examined microscopically. Harvested nodes 
were identified by a pathologist and all LN specimens were examined 
by a single genitourinary pathologist with >15 years of experience. The 
total number of LNs removed and the number of positive LNs for each 
anatomical location were recorded. Packets without any nodal tissue 
were regarded as containing zero LNs.
Clinicopathologic characteristics and perioperative outcomes were 
evaluated. Complications that were presumably associated with eLND 
were also recorded and defined according to the Clavien classification 
system.19 Quantitative variables were compared using the Mann–
Whitney U-test and qualitative variables were compared using the 
Chi-squared test or Fisher exact test. Uni- and multi-variate logistic 
regression analyses were conducted to identify preoperative variables 
that predict LN invasion after eLND. The Statistical Package for Social 
Science for Windows, version 12.0 (SPSS Inc., Chicago, IL, USA) was 
used for all statistical analyses. P < 0.05 was considered as significant, 
and all P values were two-sided.
RESULTS
Robotic eLND was performed in 147 patients; patient characteristics 
are summarized in Table 1. Mean age at surgery was 65.3 years and 
median PSA was 10.7 ng ml−1. A total of 108 patients (73.5%) were 
classified in the D’Amico high-risk group. The median operation time 
for eLND was 47 min (interquartile range (IQR): 35–56, range 24–100). 
The median estimated blood loss from RARP with eLND was 250 ml, 
and no patient received a blood transfusion. Of the 147  patients, 
24 (16.3%) had LN metastases. The incidence of LN metastases was 
correlated with Gleason score and tumor stage. A total of 97 positive 
LNs were found, and the median number of positive LNs in patients 
with LN metastases was two (IQR 1–5, range 1–21).
Overall, a median of 22 LNs  (IQR 18–26, range 11–57) were 
removed from all patients. The mean number of LNs per patient in each 
packet is illustrated in Figure 1. There was no difference in the median 
number of LNs removed between the right and left sides (10 vs 11, 
respectively, P = 0.558). Periprostatic fat tissues overlying the prostate 
and vesicoprostatic junction were also removed. Twelve patients (8.2%) 
had LNs in the periprostatic area. In these patients, the median number 
of LNs removed was one and the range was from 1 to 5.
The obturator fossa was the most common site for LN 
metastases. The number of positive LNs removed from this area 
consisted of 42.3% of all positive LNs (41/97) and 50% of patients 
Table 1: Clinicopathological characteristics of all patients
All (n=147) LN (−) (n=123) LN (+) (n=24) P
Age (year)
Mean±s.d. 65.3±7.0 65.3±6.4 66.4±7.2 0.468
Median, IQR 66, 62–70 66, 62–70 66, 62–70
BMI (kg m−2)
Mean±s.d. 24.2±2.3 24.2±2.2 24.0±2.8 0.704
Median, IQR 24.2, 22.4–25.6 24.2, 22.5–25.6 24.3, 21.4–25.8
PSA (ng ml−1)
Mean±s.d. 15.6±17.9 13.2±11.6 28.1±33.9 0.043
Median, IQR 10.7, 6.5–17.4 10.1, 6.1–15.7 16.7, 10.1–25.8
Biopsy Gleason 
score, n (%)
6 19 (12.9) 18 (14.6) 1 (4.2) 0.007
7 57 (38.8) 52 (42.3) 5 (20.8)
8–10 71 (48.3) 53 (43.1) 18 (75.0)
Total biopsied 
cores
Mean±s.d. 11.6±3.5 11.5±3.4 11.9±3.5 0.653
Median, IQR 12, 10–12 12, 10–12 12, 10–12
Number positive 
cores
Mean±s.d. 4.2±2.9 3.8±2.5 6.2±3.6 0.004
Median, IQR 3, 2–6 3, 2–5 5, 3–9
Percentage of 
positive cores
Mean±s.d. 37.9±25.2 34.6±22.8 54.3±30.3 0.005
Median, IQR 33, 17–50 30, 16–50 51, 25–81
Clinical T stage, 
n (%)
T1 80 (54.4) 75 (61.0) 5 (20.8) <0.001
T2 44 (29.9) 37 (30.1) 7 (29.2)
T3 23 (15.7) 11 (8.9) 12 (50.0)
D’Amico risk 
group, n (%)
Intermediate 39 (26.5) 37 (30.1) 2 (8.3) 0.040
High 108 (73.5) 86 (69.9) 22 (91.7)
Number LNs 
removed
Mean±s.d. 22.5±7.18 22.2±6.5 23.8±9.9 0.328
Median, range 22, 18–26 22, 18–26 21, 16–26
Pathologic 
Gleason score, 
n (%)
6 15 (10.2) 14 (11.4) 1 (4.2) 0.007
7 78 (53.1) 70 (56.9) 8 (33.3)
8–10 54 (36.7) 39 (31.7) 15 (62.5)
Pathologic T 
stage, n (%)
T2 82 (55.8) 77 (62.6) 5 (20.8) <0.001
T3a 39 (26.5) 35 (28.5) 4 (16.7)
T3b 26 (17.7) 11 (8.9) 15 (62.5)
IQR: interquartile range; s.d.: standard deviation; BMI: body mass index; 
PSA: prostate‑specific antigen; LNs: lymph nodes
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with LN metastases  (12/24) had a positive LN in the obturator 
fossa  (Figure  2). However, only four patients  (16.7%, 4/24) had 
a single positive LN packet in the obturator fossa. The internal 
iliac area was the most common area to find a single positive LN 
packet  (20.8%, 5/24). Eight patients (33.3%, 8/24) had positive 
LNs at the common iliac area, and three of these patients (12.5%, 
3/24) had no intrapelvic LN involvement. Of the 12 patients who 
had LNs in the periprostatic area, only one had positive LNs. This 
patient had 14 positive LNs in both the pelvic and common iliac 
area. The rate of LN positivity did not differ between groups when 
patients were stratified by the median number of LNs removed (<22 
vs ≥ 22; Table 2). On univariate logistic regression analysis, PSA, 
clinical stage, biopsy Gleason score, and percentage of positive cores 
were significantly associated with LN metastases. On multivariate 
analysis, PSA  (P  =  0.021) and clinical stage  (P  =  0.017) were 
independent predictors of LN metastases, while biopsy Gleason 
score and percentage of positive cores lost statistical significance 
after controlling for other variables (Table 3).
Complications associated with LND occurred in 21 patients (14.3%). 
Clavien Grade 3 complications were observed in three patients (2.0%) 
who underwent percutaneous drainage for symptomatic lymphocele. 
Symptomatic lymphocele was found in five patients  (3.4%) and 
two patients were treated conservatively. Of the five patients with 
symptomatic lymphocele, one was diagnosed 3 months after surgery 
owing to spiking fever, while the others were diagnosed during 
their postoperative hospital stay. Lymphedema was observed in 
15 patients (10.2%), which resolved after physical treatment in most 
patients. Only three patients (2.0%) showed mild persistent symptoms. 
Neuropraxia was observed in one patient  (0.7%), which resolved 
spontaneously 3 months after surgery.
Figure 1: Mean number of lymph nodes removed from each anatomic location.
Figure 2: (a) Anatomical distribution of 97 positive lymph nodes (LNs) in 24 patients with LN metastases, (b) and the number of patients with positive LNs 
and a single positive LN packet from each anatomic location.
ba
Table 3: Uni‑ and multi‑variate logistic regression analysis for 
prediction of LN metastases
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
PSA 1.04 (1.01–1.07) 0.005 1.04 (1.00–1.07) 0.021
Clinical stage (≥T2 vs T1) 5.93 (2.07–16.9) 0.001 3.93 (1.27–12.1) 0.017
Biopsy Gleason score 0.024 0.070
≤6 1 1
7 1.73 (0.18–15.8) 0.627 1.95 (0.14–26.5) 0.614
≥1 6.11 (0.76–49.1) 0.089 6.68 (0.55–80.9) 0.135
Percentage positive cores 1.02 (1.01–1.04) 0.001 1.01 (0.99–1.03) 0.072
PSA: prostate‑specific antigen; OR: odds ratio; CI: confidence interval
Table 2: Clinicopathological characteristics of patients according to the 
number of LNs removed
LNs removed<22 
(n=73)
LNs removed≥22 
(n=74)
P
Mean age (year)±s.d. 65.5±6.8 65.5±6.2 0.995
Mean BMI (kg m−2)±s.d. 24.3±2.2 24.0±2.4 0.442
Mean PSA (ng ml−1)±s.d. 14.0±13.2 17.3±21.7 0.267
Pathologic Gleason score, n (%)
6 8 (11.0) 7 (9.5) 0.722
7 39 (53.4) 39 (52.7)
8–10 26 (35.6) 28 (37.8)
Pathologic T stage, n (%)
T2 41 (56.2) 41 (55.4) 0.967
T3a 19 (26.0) 20 (27.0)
T3b 13 (17.8) 13 (17.6)
LN metastases, n (%) 12 (16.4) 12 (16.2) 0.971
Mean number LN removed±s.d. 
(median, IQR)
17.1±3.0
(18, 15–20)
27.8±6.0
(26, 24–31)
<0.001
s.d.: standard deviation; BMI: body mass index; PSA: prostate‑specific antigen; 
IQR: interquartile range; LNs: lymph nodes
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DISCUSSION
The definition and extent of eLND vary between studies.14,20,21 
Some authors have suggested that the total number of LNs removed 
contributes to staging accuracy and LN count was thus a determining 
factor for eLND.10,22 However, the number of LNs can vary among 
patients according to the way the specimen were handled by 
pathologists or the method by which the LN specimens were submitted 
to pathology.23 In the current study, we found no significant difference 
in the incidence of LN metastases according to the number of LNs 
removed. Furthermore, the LND template seems to be more important 
than the number of LNs removed.
While eLND is commonly considered to be the removal of 
lymphatic tissues in the intrapelvic area (external iliac, obturator, 
internal iliac), in this study we also removed common iliac nodes up 
to the ureteric crossing and periprostatic lymphofatty tissues. This 
template that includes the common iliac area is based on the results of 
a multimodality mapping study. 21 The mapping study demonstrated 
that extending the template up to the ureteric crossing removes 
approximately 75% of all prostate primary lymphatic landing sites, 
while only 63% are located in the intrapelvic area. In this study, we 
observed that 22.7% of positive LNs were found in the common iliac 
area, and three patients (12.5%, 3/24) had positive LNs exclusively in 
this area without intrapelvic involvement.
While no consistent conclusion has been reached regarding the 
extent of LND, it is generally agreed that the LNs in the internal iliac 
area should be removed. Many researchers have demonstrated that up 
to 50% of positive LNs are found in the internal iliac area.9,24,25 Even 
though the mean number of LNs in the internal iliac area was almost 
one-fifth of those in the external iliac area in this study, the number 
of positive LNs was not significantly different between the external 
iliac and internal iliac areas  (17 and 15 positive LNs, respectively). 
While a portion of the internal iliac LNs can be sent as obturator LNs, 
meticulous dissection of the internal iliac area should be recommended 
and emphasized to all robotic surgeons.
We routinely removed fatty tissue in the periprostatic area. In 
RARP, surgeons commonly remove the periprostatic fatty tissue to 
clearly expose the apex of the prostate and vesicoprostatic junction. It 
was previously reported that approximately 15% of patients had LNs 
in the periprostatic area and LN involvement was exclusively found 
in the periprostatic area in some of these patients.26 In our study, 
cohort of patients with intermediate and high-risk prostate cancer, 
12 patients (8.2%) had LNs in the periprostatic area, and positive LNs 
were found in one patient who had multiple LN metastases. In addition, 
we found that another patient had up to five LNs in the periprostatic 
area. Thus, we believe that meticulous removal of periprostatic tissue 
might improve LND staging accuracy.
The therapeutic role of LND is one of the main contentious issues in 
prostate cancer treatment to date. Some authors have suggested that LND 
may improve prostate cancer outcome by eliminating micrometastatic 
disease that might otherwise progress and subsequently disseminate 
systemically. Recently, the first randomized controlled study to assess 
the impact of LND extent on biochemical outcome was published. 
While the biochemical outcome in the aforementioned study did not 
differ according to LND extent in low-risk patients, eLND positively 
affected biochemical outcomes in intermediate and high-risk patients.27 
Moreover, long-term oncologic outcomes of patients with LN metastases 
were favorable, and some remained free of biochemical recurrence after 
LND.28,29 Although there is no level 1 evidence demonstrating improved 
cancer specific survival by LND, increasing evidence suggests that LND 
may confer a survival benefit.
A recent study that analyzed data from the Surveillance, 
Epidemiology, and End Results cancer registry reported that there was 
a significant decline in the use of LND with the increased prevalence of 
RARP.4 This trend is attributable to a surgeon’s concern with functional 
outcomes over oncologic outcomes, and the omission of LND during 
early segments of the learning curve. Regardless of surgical modality, 
eLND is still recommended in patients with a risk of LN metastases 
and RARP should not be a determining factor for not performing 
LND.4,11,13 The technical feasibility of eLND has been reported in 
previous studies,14–16 and we have also demonstrated that LN yield and 
LN positive rate achieved using robotic techniques are comparable to 
those achieved in open series.25,30
This study has several limitations. Although data were collected 
prospectively, patients with missing data due to undefined locations 
from which the pathological specimens were obtained were excluded 
from the analysis. With respect to pathological examination, additional 
analyses of LN specimens, such as immunohistochemical staining 
or real-time polymerase chain reaction, were not performed even 
though they are known to increase the detection rate of LN metastases 
when conventional histopathology is negative.31,32 Finally, data on 
nerve sparing or postoperative erectile function were not included 
in the analysis owing to incomplete information. Thus, we could not 
evaluate the impact of eLND on postoperative erectile function. Despite 
these limitations, the strengths of our study include the fact that the 
surgeries were all performed by a single, experienced surgeon, that 
LND was performed using a consistent technique and template during 
the study period, and that all patients adhering to a uniform protocol. 
In this study, we assessed the technical feasibility of robotic eLND 
and evaluated LN yield and metastasis distribution. Further studies 
are needed to evaluate the oncologic outcome of LND with different 
dissection templates and longer-term follow-up.
CONCLUSIONS
Robotic eLND is technically feasible and can be performed with 
minimal morbidity. Furthermore, the LN yield and node positive rate 
achieved using the robotic technique is comparable to those of open 
series. Rates of LN metastases were not influenced by the number of 
LNs removed when a consistent extended template and dissection 
technique were applied. The robotic technique is not a prohibitive 
factor for performing eLND.
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